Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air (VRNA)

Update: where does ensifentrine stand vs. Regeneron's dupixent On March 23, Regeneron/Sanofi reported data on dupixent's phase 3 COPD trial. Following the recent data readout of Regeneron's Dupixent, a biologic currently being evaluated in two Phase 3 studies for moderate-to-severe COPD patients…#regeneron #regeneronsanofi #veronapharma #vrna #boreas #phase3 #enhance1 #dupixent #ensifentrine #medicare
Source: Reuters: Health - Category: Consumer Health News Source Type: news